Chi Van Dang

Scientific Director, Ludwig Institute for Cancer Research; Professor, Wistar Institute

“As a biomedical researcher, the emergence of immunotherapies for cancer patients has provided me and others across the industry with such opportunities. The tangible impact on clinical outcomes of these treatments is evident. However, we are still challenged by why many patients don’t have durable responses and additional research will be critical to overcoming this barrier and achieving more cancer cures.”

Part of the Power List 2019

Breakthroughs at the bench, novel technologies and groundbreaking policies and regulation have helped the pharma industry grow from strength to strength. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.

Go to The Power List 2019